Oric Pharmaceuticals Inc
$ 8.25
-2.14%
26 Dec - close price
- Market Cap 803,462,000 USD
- Current Price $ 8.25
- High / Low $ 8.43 / 8.15
- Stock P/E N/A
- Book Value 4.18
- EPS -1.71
- Next Earning Report 2026-02-17
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.25 %
- ROE -0.40 %
- 52 Week High 14.93
- 52 Week Low 3.90
About
Oric Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, focused on revolutionizing cancer treatment through the innovation of targeted therapies. Utilizing proprietary drug development platforms, Oric addresses significant unmet medical needs in oncology, specifically in overcoming treatment resistance. With a robust pipeline designed to target critical mechanisms that enable cancer cell survival, the company is advancing its therapeutic candidates through pivotal clinical trials, positioning itself to provide novel treatment options for patients with challenging malignancies.
Analyst Target Price
$20.92
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-13 | 2025-08-12 | 2025-05-05 | 2025-03-10 | 2024-11-04 | 2024-08-12 | 2024-05-06 | 2024-03-11 | 2023-11-06 | 2023-08-10 | 2023-05-08 | 2023-03-16 |
| Reported EPS | -0.33 | -0.47 | -0.42 | -0.51 | -0.49 | -0.45 | -0.37 | -0.49 | -0.44 | -0.5 | -0.53 | -0.52 |
| Estimated EPS | -0.4 | -0.44 | -0.44 | -0.5084 | -0.4717 | -0.41 | -0.44 | -0.49 | -0.46 | -0.57 | -0.54 | -0.54 |
| Surprise | 0.07 | -0.03 | 0.02 | -0.0016 | -0.0183 | -0.04 | 0.07 | 0 | 0.02 | 0.07 | 0.01 | 0.02 |
| Surprise Percentage | 17.5% | -6.8182% | 4.5455% | -0.3147% | -3.8796% | -9.7561% | 15.9091% | 0% | 4.3478% | 12.2807% | 1.8519% | 3.7037% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-17 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.33 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ORIC
2025-12-22 07:14:00
This article discusses Oric Pharmaceuticals Inc. (NASDAQ: ORIC) and the implications of price-sensitive allocations based on AI analysis. It highlights weak near and mid-term sentiment but a strong long-term outlook, alongside various trading strategies and risk parameters. The analysis includes support and resistance levels across different time horizons.
2025-12-20 11:09:37
Dominic Piscitelli, CFO of Oric Pharmaceuticals, Inc., engaged in insider trading activities. On December 15, 2025, he acquired 29,333 shares through restricted stock unit settlements. The following day, on December 16, 2025, he sold 10,720 shares at an average price of $9.0604 to cover tax withholding obligations associated with the RSU vesting.
2025-12-20 11:09:37
Oric Pharmaceuticals, Inc. reported insider trading activity involving its President and CEO. On December 15, 2025, the executive acquired 83,666 shares of common stock at no cost through RSU vesting. The following day, 33,374 shares were sold for $9.06 per share to cover tax obligations, resulting in the executive beneficially owning 581,711 shares directly.
2025-12-18 01:09:33
Oric Pharmaceuticals CEO Jacob Chacko sold 33,374 shares of the company's stock for $302,368. The sale reduced his stake by 5.43% to 581,711 shares. This transaction is part of a pattern of recent insider selling by Chacko, with the stock trading down 9.9% on heavy volume following the disclosure.
2025-12-18 01:09:33
Oric Pharmaceuticals (NASDAQ:ORIC) CFO Dominic Piscitelli sold 10,720 shares of the company's stock on December 16th, reducing his ownership by 13.59%. This transaction, valued at $97,123.20, decreases his direct holdings to 68,148 shares. The company's stock currently trades at $8.22, significantly below the analyst consensus target price of $19.67, with strong institutional ownership.
2025-12-18 01:09:33
Oric Pharmaceuticals insider Pratik Multani sold 10,720 shares of the company's stock on December 16th at an average price of $9.06, totaling $97,123.20. This transaction reduced his direct ownership by 13.59% to 68,149 shares. The company's stock traded down to $8.22 on Wednesday, and analysts currently have a "Moderate Buy" rating with an average target price of $19.67.
